Alison McDowall

Alison McDowall

Auto-generated profile, based on publicly available information

Alison McDowall

University of Cambridge

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2022 in Research Square
Verified
Preprint
Open access
PDF file
ANAndreas Neerincx
Andreas Neerincx
AAAure Aflalo
Aure Aflalo
IHIda Hafstrand
Ida Hafstrand
ATAlice Torres
Alice Torres
AMAlison McDowall
Alison McDowall
LBLouise Boyle
Louise Boyle
Low tumour immunogenicity is a major hurdle to overcome in the treatment of cancers with immunotherapies. Here, we reveal a novel therapeutic approach to increase tumour immunogenicity. By delivering the major histocompatibility complex class I (MHC-I) peptide exchange catalyst TAPBPR in an antibody-mediated manner onto the plasma membrane of tumour cells, extracellular MHC-I become highly peptide-receptive. Upon exposure to low doses of exogenous peptide, MHC-I molecules on tumour cells are efficiently loaded with immunogenic antigens, including those derived from human cytomegalovirus and Epstein-Barr virus. TAPBPR-antibody fusion proteins were delivered specifically to tumours in vivo. Finally, antigen-specific CD8+ T cells respond to tumour cells in a targeted manner and can mediate killing of antibody target-positive cells. As memory T cells specific for previously encountered common viruses patrol tumours, TAPBPR-based therapeutics could offer an attractive means to redirected virus-specific T cells against tumours in the fight against cancer.